Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

High Throughput Screening

By Drug Discovery Trends Editor | May 9, 2008

Panasonic and Kalypsys HTS systemPanasonic Factory Solutions Co., Ltd. (PFSC), Panasonic Factory Solutions Company of America (PFSA), and Kalypsys, Inc. established a joint commercialization agreement to enhance support for a next-generation high throughput screening (HTS) system. This modular HTS system enables a shortening of the drug discovery development period by screening new drug candidates (compounds) at high speed with 1536-well high-density plates.

The module size is compactly standardized and a variety of screening-related functions are included. The system is not limited to the boundaries of current screening; it has the extendibility to be easily adapted to a wide range of assay applications in the new drug development process.

The system includes reliability-enhancing technologies such as reducing edge effect (uneven evaporation of cell culture medium within plates) as well as dispense nozzle clogging prevention and an assay data management system. Bidirectional conveyor belt plate-handling realizes 1 min/1536-well plate throughput with high data integrity—resulting in high-speed processing.

www.panasonicfa.com
www.kalypsys.com 

This article was published in Drug Discovery & Development magazine: Vol. 11, No. 5, May, 2008, pp. 10.


Filed Under: Drug Discovery

 

Related Articles Read More >

Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50